CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $5.74M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.74BEUR10.21B · vs all stocks (USD)
Revenue (TTM)
4.92MEUR5.74M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.2260xvs all stocks
52-Week Change
53.38%vs all stocks
Market Capitalization
8.74BEUR10.21B · vs all stocks (USD)
Enterprise Value
7.70BEUR8.99B · vs all stocks (USD)
Forward P/E
-38.92xvs Biotechnology peers
Price to Book (MRQ)
19.08xvs Biotechnology peers
Enterprise to Revenue
1.57Kxvs Biotechnology peers
Enterprise to EBITDA
-30.32xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-4183.70%vs Biotechnology peers
Return on Assets (TTM)
-44.65%vs Biotechnology peers
Return on Equity (TTM)
-157.07%vs Biotechnology peers
Revenue (TTM)
4.92MEUR5.74M · vs all stocks (USD)
Revenue per Share (TTM)
0.0670EURUpdated Aug 21, 2026Quarterly Revenue Growth
35.20%vs Biotechnology peers
Gross Profit (TTM)
4.92MEUR5.74M · vs all stocks (USD)
EBITDA (TTM)
-254.00MEUR-296.56M · vs all stocks (USD)
Net Income (TTM)
-332.20MEUR-387.86M · vs all stocks (USD)
Operating Cash Flow (TTM)
-178.37MEUR-208.25M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-114.47MEUR-133.65M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00EURFY2025 · Dec 31, 2025Operating Income
-246.06MEUR-287.28M · vs all stocks (USD)
Pre-tax Income
-330.25MEURFY2025 · Dec 31, 2025Income Tax Expense
5.85MEURFY2025 · Dec 31, 2025Net Income
-336.10MEURFY2025 · Dec 31, 2025EBIT
-301.77MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-268.99MEURFY2025 · Dec 31, 2025Research & Development
177.76MEURFY2025 · Dec 31, 2025Selling, General & Administrative
72.86MEURFY2025 · Dec 31, 2025Other Operating Expenses
-4.57MEURFY2025 · Dec 31, 2025Non-operating Interest Income
5.75MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
28.48MEURFY2025 · Dec 31, 2025EPS (Basic)
-4.83EURFY2025 · Dec 31, 2025EPS (Diluted)
-4.83EURFY2025 · Dec 31, 2025Basic Shares Outstanding
69.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
69.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-336.10MEURFY2025 · Dec 31, 2025Operating Cash Flow
-270.21MEURFY2025 · Dec 31, 2025Free Cash Flow
-270.35MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
516.68MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-336.10MEURFY2025 · Dec 31, 2025Depreciation & Amortization
1.07MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
5.85MEURFY2025 · Dec 31, 2025Stock-based Compensation
35.40MEURFY2025 · Dec 31, 2025Other Non-cash Items
22.03MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
7.04MEURFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-6.21MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
710.00KEURFY2025 · Dec 31, 2025Capital Expenditures
-142.00KEURFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00EURFY2025 · Dec 31, 2025Other Investing Activity
-13.58MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-13.72MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00EURFY2025 · Dec 31, 2025Long-term Debt Payments
-59.53MEURFY2025 · Dec 31, 2025Common Dividends Paid
0.00EURFY2025 · Dec 31, 2025Other Financing Charges
-40.61MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
547.98MEURFY2025 · Dec 31, 2025Shares Outstanding
79.29MSharesUpdated Aug 21, 2026Float Shares
69.36MSharesUpdated Aug 21, 2026% Held by Insiders
4.85%vs all stocks
% Held by Institutions
48.06%vs all stocks
Total Cash (MRQ)
491.55MEUR573.91M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.20EURUpdated Aug 21, 2026Total Debt (MRQ)
34.21MEUR39.94M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0796xvs Biotechnology peers
Current Ratio (MRQ)
8.25xvs Biotechnology peers
Book Value per Share (MRQ)
5.42EURUpdated Aug 21, 2026Total Assets
584.34MEUR682.24M · vs all stocks (USD)
Total Current Assets
551.24MEURFY2025 · Dec 31, 2025Total Liabilities
129.14MEURFY2025 · Dec 31, 2025Total Non-current Assets
33.10MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
66.11MEURFY2025 · Dec 31, 2025Total Current Liabilities
63.02MEURFY2025 · Dec 31, 2025Cash
38.14MEURFY2025 · Dec 31, 2025Cash Equivalents
478.54MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
516.68MEURFY2025 · Dec 31, 2025Other Short-term Investments
13.70MEURFY2025 · Dec 31, 2025Accounts Payable
37.55MEURFY2025 · Dec 31, 2025Short-term Debt
1.30MEURFY2025 · Dec 31, 2025Deferred Revenue
0.00EURFY2025 · Dec 31, 2025Long-term Debt
554.00KEURFY2025 · Dec 31, 2025Other Non-current Liabilities
30.24MEURFY2025 · Dec 31, 2025Common Stock (Book)
785.00KEURFY2025 · Dec 31, 2025Retained Earnings
-738.48MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
455.20MEUR531.47M · vs all stocks (USD)
52-Week Low
60.45EURUpdated Aug 21, 202652-Week High
139.00EURUpdated Aug 21, 202652-Week Change
53.38%vs all stocks
Beta
-0.2260xvs all stocks
50-Day MA
106.41EURUpdated Aug 21, 2026200-Day MA
103.22EURUpdated Aug 21, 2026Avg 10-Day Volume
86.58KSharesUpdated Aug 21, 2026Avg 30-Day Volume
115.79KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-4.61EURUpdated Aug 21, 2026Other Income / Expense
-31.71MEURFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $5.74M, lower than 95% of all stocks globallySignificant
Revenue (USD): 5,744,296.8Global P5: 30,274,777.221
Market cap is $10.21B, above the global median of $1.15BNotable
Market cap (USD): 10,207,604,274.101Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Globus Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Krystal Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arrowhead Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
RemeGen Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lupin Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nuvalent, Inc.
Tier 1ProductionApproval-Gated PipelineRule